CYP2D6 and breast carcinoma: When separately analyzing premenopausal patients, no effect of CYP2D6 activity was found on relapse (aHR 0.99, CI 0.69; 1.42), or breast cancer specific mortality (aHR 1.14, CI 0.63; 2.05).